Xeris Biopharma (XERS) earnings, Nov 5, 2026: EPS +1,124%, stock +25.0%
In brief
Xeris Biopharma reported on Nov 5, 2026. Earnings per share changed +1,124% year over year, 89.5% above the estimate; revenue +44%. The stock opened with a +19.6% gap and closed the day +25.0% (Nov 5, 2026). The stock is now 4.8% below its 52-week high, +32.5% over 12 months.
EPS vs estimate+89.5%
EPS, YoY+1,124%
Revenue, YoY+44%
Gap · day+19.6% · +25.0%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | −11.3% | −9.2% |
| Nov 5, 2026 | +19.6% | +25.0% |
Next-quarter estimates, ratings and the XERS chart are in the terminal.
Open the terminalFAQ
When is Xeris Biopharma's next earnings report?
There is no new date in the data yet: companies announce it a few weeks ahead.
How did Xeris Biopharma stock react to the report?
Opening gap +19.6%, day's result +25.0%.
Did Xeris Biopharma's earnings grow?
Earnings per share rose 1,124% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.